Back to top
more

Cidara Therapeutics (CDTX)

(Delayed Data from NSDQ)

$13.44 USD

13.44
40,727

-0.17 (-1.25%)

Updated May 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for March 5th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Cidara Therapeutics (CDTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 14.58% and -32.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cidara Therapeutics (CDTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -87.50% and -79.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock

by Zacks Equity Research

Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Cidara Therapeutics (CDTX) a New Buy Stock

by Zacks Equity Research

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -44.83% and -83.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Sell Stocks for January 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

What Makes Cidara Therapeutics (CDTX) a New Buy Stock

by Zacks Equity Research

Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cidara Therapeutics (CDTX) Enters Oversold Territory

by Zacks Equity Research

Cidara Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Cidara Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

    Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock

    by Zacks Equity Research

    Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.

      5 Biotech Stocks Well Poised to Surpass Expectations in Q3

      by Zacks Equity Research

      The pharma and biotech industry has demonstrated strength

        What's in the Cards for Merrimack (MACK) in Q3 Earnings?

        by Zacks Equity Research

        Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

          What's in the Cards for Repros (RPRX) This Earnings Season?

          by Zacks Equity Research

          Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

            Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season?

            by Zacks Equity Research

            Cidara Therapeutics (CDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into this earnings season.

              Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

              by Zacks Equity Research

              Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

                What's in Store for BioDelivery (BDSI) this Earnings Season?

                by Zacks Equity Research

                BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

                  What's in the Cards for Ionis (IONS) this Earnings Season?

                  by Zacks Equity Research

                  Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.

                    Arpita Dutt headshot

                    3 of the Best & Worst Performing Drug Stocks of Q1

                    by Arpita Dutt

                    Here is a look at 3 of the best and worst-performing drug stocks in the first quarter of 2017.